Search research articles
Contact Us
Filters
Showing results (11-20 of 15) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 15 results.
Plos One
|
January 5, 2017
Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation
Stefanie Ginster, Maureen Bardet, Adeline Unterreiner, et al.
Nature Communications
|
November 4, 2015
The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling
Theo Klein, Shan-Yu Fung, Florian Renner, et al.
Frontiers in Immunology
|
November 6, 2024
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors
Felix Scheuplein, Florian Renner, John E Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors
Maria Vieito, Elisa Fontana, Catherine H Han, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 13, 2015
Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation
Frédéric Bornancin, Florian Renner, Ratiba Touil, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 15) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 15 results.
Plos One
|
January 5, 2017
Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation
Stefanie Ginster, Maureen Bardet, Adeline Unterreiner, et al.
Nature Communications
|
November 4, 2015
The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling
Theo Klein, Shan-Yu Fung, Florian Renner, et al.
Frontiers in Immunology
|
November 6, 2024
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors
Felix Scheuplein, Florian Renner, John E Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors
Maria Vieito, Elisa Fontana, Catherine H Han, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 13, 2015
Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation
Frédéric Bornancin, Florian Renner, Ratiba Touil, et al.
Page
of 2